Table 1 Baseline clinical characteristics of patients with neovascular AMD.

From: Neovascular age-related macular degeneration in which exudation predominantly occurs as a subretinal fluid during anti-vascular endothelial growth factor treatment

 

Total eyes (n = 509)

No exudative recurrence (n = 54)

Presence of only SRF during a 2-year anti-VEGF treatment

P

Yes (n = 208)

No (n = 247)

Age (years ± SD)

70.1 ± 8.5

70.4 ± 9.6

69.7 ± 8.4

70.9 ± 9.2

0.197a

Sex

    

0.873b

 Male, n (%)

275 (54.0%)

28 (51.9%)

115 (55.4%)

132 (53.4%)

 

 Female, n (%)

234 (46.0%)

26 (48.1%)

93 (44.7%)

115 (46.6%)

 

Mean baseline BCVA (logMAR)

(Snellen equivalent)

0.49 ± 0.41 (20/61)

0.52 ± 0.39 (20/66)

0.39 ± 0.32 (20/49)

0.55 ± 0.42 (20/70)

0.021a

Baseline BCVA (logMAR)

(Snellen equivalent)

    

0.143b

 < 0.40 (20/50)

126 (24.7%)

14 (25.9%)

61 (29.4%)

51 (20.6%)

 

 0.40 (20/50) to 1.0 (20/200)

267 (52.5%)

30 (55.6%)

107 (51.4%)

130 (52.6%)

 

 > 1.0 (20/200)

116 (22.8%)

10 (18.5%)

40 (19.2%)

66 (26.7%)

 

Mean central foveal thickness ± SD (µm)

431 ± 188

448 ± 196

428 ± 201

433 ± 173

0.413a

Mean subfoveal choroidal thickness ± SD (µm)

264 ± 107

257 ± 121

287 ± 103

252 ± 107

0.097a

Lesion location, n (%)

    

0.123b

 Subfoveal

329 (64.6%)

35 (64.8%)

119 (57.3%)

175 (70.9%)

 

 Juxtafoveal

119 (23.4%)

10 (18.5%)

60 (28.8%)

49 (19.8%)

 

 Extrafoveal

61 (12.0%)

9 (16.7%)

29 (13.9%)

23 (9.3%)

 

Mean CNV size ± SD (mm2)

2.5 ± 2.0

2.2 ± 1.9

2.4 ± 2.2

2.8 ± 1.9

0.173a

Presence of choroidal vascular hyperpermeability, n (%)c

195 (38.3%)

18 (33.3%)

88 (42.3%)

89 (36.0%)

0.284b

Baseline fluid feature, n (%)

    

 < 0.001b

 SRF alone

196 (38.5%)

24 (44.4%)

120 (57.7%)

52 (21.1%)

 

 SRF with other exudation (IRF, hemorrhaged, or SHRM)

165 (32.4%)

15 (27.8%)

43 (20.7%)

107 (43.3%)

 

 Absence of SRF

148 (29.1%)

15 (27.8%)

45 (21.6%)

88 (35.6%)

 

Presence of PED at baseline, n (%)

 Fibrovascular PED

302 (59.3%)

30 (55.6%)

121 (58.2%)

151 (61.1%)

0.113b

 Serous PED

112 (22.0%)

9 (16.7%)

50 (24.0%)

53 (21.5%)

0.487b

PED height at baseline (µm)

281 ± 183

272 ± 233

238 ± 179

288 ± 211

0.002a

MNV subtype

    

 < 0.001b

 Type 1

259 (50.9%)

26 (48.1%)

93 (44.7%)

140 (56.7%)

 

 Aneurysmal type 1/PCV

188 (37.0%)

23 (42.6%)

108 (51.9%)

57 (23.1%)

 

 Type 2

62 (12.1%)

5 (9.3%)

7 (3.4%)

50 (20.2%)

 

Anti-VEGF agent, n (%)

    

0.336b

 Ranibizumab

121 (23.8%)

13 (24.1%)

55 (26.4%)

53 (21.5%)

 

 Aflibercept

286 (56.2%)

28 (51.9%)

120 (57.7%)

138 (55.9%)

 

 Bothe

102 (20.0%)

13 (24.0%)

33 (15.9%)

56 (22.6%)

 

Treatment regimen, n (%)

    

0.136b

 PRN

249 (48.9%)

35 (64.8%)

99 (47.6%)

115 (46.6%)

 

 T&E

172 (33.8%)

14 (25.9%)

69 (33.2%)

89 (36.0%)

 

 Bothf

88 (17.3%)

5 (9.3%)

40 (19.2%)

43 (17.4%)

 

Mean number of anti-VEGF injections ± SD

9.5 ± 4.1

8.7 ± 4.7

9.6 ± 5.1

9.4 ± 4.4

0.070a

  1. AMD, age-related macular degeneration; BCVA, best-corrected visual acuity; CNV, choroidal neovascularization; IRF, intraretinal fluid; logMAR, logarithm of the minimum angle of resolution; MNV, macular neovascularization; PCV, polypoidal choroidal vasculopathy; PED, pigment epithelial detachment; PRN, pro-re-nata; SD, standard deviation; SHRM, subretinal hyperreflective material; SRF, subretinal fluid; T&E, treat-and-extend; VEGF, vascular endothelial growth factor.
  2. ap-value by analysis of variance.
  3. bp-value by chi-square test.
  4. cIndocyanine green angiography image was not available for 38 eyes among the total eyes.
  5. dRefers to any hemorrhage, not necessarily limited to the lesion, including subretinal and sub-RPE hemorrhage.
  6. ePatients switched from an anti-VEGF drug to the other one during the study period; 74 eyes (72.5%) were switched from ranibizumab to aflibercept, while the others were switched from ranibizumab to aflibercept.
  7. fTreatment regimen was switched from PRN to T&E in 52 (59.1%) eyes and from T&E to PRN in others (40.9%) during the study period.
Back to article page